Endometrial expression of tyrosine kinase receptor (EphA2) in patients with deep infiltrating endometriosis
Objective. To assess the endometrial expression pattern of EphA2 receptor in healthy women and in ectopic epithelial cells in the presence of deep infiltrating endometriosis.Muftaidinova Sh.K., Chuprynin V.D., Faizullina N.M., Buralkina N.A., Shchegolev A.I., Faizullin L.Z., Ovodenko D.L., Asaturova A.V., Serov V.N.
Subjects and methods. EphA2 expression in the ectopic endometrium during the different phases of the menstrual cycle was comparatively examined in women with endometriosis or endometrial adenocarcinoma and in healthy women.
Results. Immunochemical studies showed that EphA2 was present in the epithelial cells of the normal endometrium in the proliferative phase and was practically absent in the secretory phase. The staining intensity was statistically significantly higher in the epithelial cells of the infiltrating ectopic endometrium than that in those of the normal endometrium in the proliferative phase and was comparable to that of EphA2 expression in endometrial cancer cells.
Conclusion. The study showed EphA2 overexpression in the epithelial cells of the infiltrating ectopic endometrium. Thus, in addition to its diagnostic value, modulation of the activity of these receptors in endometriosis can serve as a therapeutic target.
Keywords
deep infiltrating endometriosis
endometrial cancer
angiogenesis
EphA2 receptor
References
- Clement P.B. The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathology. 2007; 14(4): 241–60. http://dx.doi.org/10.1097/PAP.0b013e3180ca7d7b
- Giudice L.C. Clinical practice: endometriosis. N. Engl. J. Med. 2010; 362: 2389–98. . doi: 10.1056/NEJMcp1000274.
- Czyzyk A., Podfigurna A., Szeliga A., Meczekalski B. Update endometriosis pathogenesis. Minerva Ginecol. 2017; 69(5): 447–61. doi: 10.23736/S0026-4784.17.04048-5.
- Kokcu A. Relationship between endometriosis and cancer from current perspective. Arch Gynecol Obstet. 2011; 284(6): 1473–9. doi: 10.1007/s00404-011-2047-y.
- Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. F1000Res. 2019; 8. pii: F1000 Faculty Rev-529. 2019; 14 (4); 422-469
- Salem A.F., Wang S., Billet S., Chen J. F., Udompholkul P., Gambini L., Baggio C., Tseng H. R., Posadas E. M., Bhowmick N. A., Pellecchia M. Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic PeptideDrug Conjugate. Journal of medicinal chemistry. J Med Chem. 2018; 61(5): 2052–61. doi: 10.1021/acs.jmedchem.7b01837.
- McCarty K.S. Jr, Miller L.S., Cox E.B., et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985; 109: 716–721.
- Samimi M., Pourhanifeh M.H., Mehdizadehkashi A., Eftekhar T., Asemi Z. The role of inflammation, oxidative stress, angiogenesis, and apoptosis in the pathophysiology of endometriosis: Basic science and new insights based on gene expression. J Cell Physiol. 2019; 234(11): 19384–92. doi: 10.1002/jcp.28666.
- Kajiyama H., Suzuki S., Yoshihara M., Tamauchi S., Yoshikawa N., Niimi K, Shibata K., Kikkawa F. Endometriosis and cancer. Free Radic Biol Med. 2019; 133: 186–92. doi: 10.1016/j.freeradbiomed.2018.12.015.
- Neill T., Buraschi S., Goyal A., et al. EphA2 is a functional receptor for the growth factor progranulin. J Cell Biol. 2016; 215: 687–703.
- Ieguchi K., Maru Y. Roles of EphA1/A2 and ephrin-A1 in cancer. Cancer Sci. 2019; 110(3): 841–8. doi: 10.1111/cas.13942.
- Herrem C.J., Tatsumi T., Olson K.S., et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res. 2005; 11: 226–231.
- Cazzamalli S., Dal Corso A., Widmayer F., Neri D. Chemically defined antibody- and small molecule-drug conjugates for in vivo tumor targeting applications: a comparative analysis. J Am Chem Soc. 2018; 140(5): 1617–21. doi: 10.1021/jacs.7b13361.
- Wu B., Wang S., De S.K., Barile E., Quinn B.A., Zharkikh I., Purves A., Stebbins J.L., Oshima R.G., Fisher P.B., Pellecchia M. Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cell. Chem Biol. 2015; 22(7): 876–87. doi: 10.1016/ j.chembiol.2015.06.011.
- Jin J., Pawson T. Modular evolution of phosphorylation-based signalling systems. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012; 367: 2540–55.
- Goldman-Wohl D., Greenfield C., Haimov-Kochman R., Ariel I., Anteby E.Y., Hochner-Celnikier D., Farhat M., Yagel S. Eph and ephrin expression in normal placental development and preeclampsia. Placenta. 2004; 25(7): 623–30. doi: 10.1016/ j.placenta.2004.01.016.
- Barile S., Wang S.K., Das R,. Noberini R., Dahl J.L., Stebbins E.B., Pasquale P.B., Fisher M., Pellecchia. Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system. ChemMedChem. 2014; 9: 1403–12.
Received 05.09.2019
Accepted 04.10.2019
About the Authors
Shahnoza K. Muftaydiniva, graduate student, National Medical Research Center for Obstetrics, Gynecology and Perinatology. 117997, Russia, Moscow, Ac. Oparina Str. 4.Chuprynin Vladimir Dmitrievich, PhD, Head of the Department of General Surgery, Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina Str. 4. Tel.: +74954387833. E-mail: v_chuprynin@oparina4.ru
Nafisa M. Faizullina, ayzullina Nafisa Mynavarovna, PhD., Senior Research Associate, Pathology Department Kulakov NMRC OGP, Ministry of Healthcare of the Russian Federation. Tel.: +7 (495) 438-11-83. E-mail: nafisa05@inbox.ru. 117997, Russia, Moscow, Ac. Oparina Str. 4.
Natalya A. Buralkina, doctor of Medical Sciences, Senior Researcher, the second gynecological department, Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia. Tel.: +74954387833. E-mail: n_buralkina@oparina4.ru. 117997, Russia, Moscow, Ac. Oparina Str. 4.
Aleksandr I. Shchegolev, MD, professor, head of the Department of Morbid Anatomy, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after Academician V.I. Kulakov, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel: +74955314444. E-mail: ashegolev@oparina4.ru
Leonod Z. Faizullin, Cand. Sc. (Biology), Leading Researcher, Laboratory of Molecular Genetic Methods, Research Center of Obstetrics, Gynecology and Perinatology,
Ministry of Health of Russia. Tel.: +79167106789. E-mail: l_faizullin@oparina4.ru 117997, Russia, Moscow, Ac. Oparina 4.
Dmitriy L. Ovodenko, PhD, oncogynecologist, Department of combined and integrated methods of treatment of gynecological diseases, Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia. Tel.: +74954380988. E-mail: d_ovodenko@oparina4.ru. 117485, Russia, Moscow, Ac. Oparina str. 4.
Aleksandra V. Astaurova, Ph.D., Senior Researcher at the Department of Anatomic Pathology, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology of Ministry of Health of Russia, Moscow.. E-mail: a_asaturova@oparina4.ru, Phone: 8(926)994-4314. 117997, Russia, Moscow, Ac. Oparina str. 4.
Vladimir N. Serov, MD, professor, academician of the Russian Academy of Sciences, chief researcher, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after Academician V.I. Kulakov, Ministry of Health of Russia. Тel.: +74954387287. E.mail: v_serov@oparina4.ru
117997, Russia, Moscow, Ac. Oparina str. 4.
For citation: Muftaidinova Sh.K., Chuprynin V.D., Faizullina N.M., Buralkina N.A., Shchegolev A.I., Faizullin L.Z., Ovodenko D.L., Asaturova A.V., Serov V.N. Endometrial expression of tyrosine kinase receptor (EphA2) in patients with deep infiltrating endometriosis.
Akusherstvo i Ginekologiya/ Obstetrics and gynecology. 2020; 3: 110-14. (In Russian).
https://dx.doi.org/10.18565/aig.2020.3.110-114
Similar Articles
